General Information

Neupogen has been approved for its fifth indication: to reduce the time to neutrophil recovery and the duration of fever following chemotherapy treatment in patients being treated for acute myeologenous leukemia. Patients with this type of leukemia can now receive Neupogen to improve their ability to tolerate essential chemotherapy treatments.